Features and Benefits
- Human-derived product rich in growth factors and proteins that maximize cell growth
- Pooled from multiple donors
- Manufactured to reduce lot-to-lot variation
- Extensive serology testing ensures safety for each lot
- Improves proliferation of MSCs compared to FBS without loss of phenotype
- Enhances genetic stability in stem cell cultures
- Extensive pre-testing on batches
- Increases cell growth kinetics and reduce cell doubling time
- Enhances stem cell proliferation and reduces supplementation
- Maintenance of cell phenotype and differentation potential
Cumulative population doubling of bone marrow-derived MSC was higher in PLSOLUTION compared to FBS.
Proliferation of human bone marrow-derived MSC increased in a concentration-dependent manner with PLMATRIX, PLSOLUTION an FBS, respectively.
Osteogenic and adipogenic differentation potential of human bone marrow-derived MSC in FBS, PLSOLUTION and PLMATRIX.
- Human Mesenchymal Stromal Cells from Bone Marrow (hMSC-BM)
- Human Mesenchymal Stromal Cells from Umbilical Cord (hMSC-UC)
- Human Mesenchymal Stromal Cells from Adipose Tissue (hMSC-AT)
- Human Dermal Fibroblasts (HDF)
- Standard testing of donor for infectious diseases
- Sterilized by 0.1 µm filtration (mycoplasma-free)
Final product testing for microbial and endotoxin contamination
- Quality control testing carried out in a certified test laboratory
Note: Despite all testing, proper safety precautions for potentially infectious agents must be taken. All human blood products
should be handled in accordance with currently acceptable biosafety practices and guidelines for the prevention of blood borne viral infections.
- bFGF and EGF-qualified
- Human MSC and dermal fibroblasts-qualified
- Sample aliquots available for testing in your specific conditions
- Lot reservations are available
Technical data sheets and other technical information are available upon request.
Please complete this web form to receive requested product documentation and pricing.
- Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy. 2014; 16(2):170-180
- Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use. Cytotherapy. 2013; 15(9):1086-1097
- Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identificaton of active components. Cytotherapy. 2012; 14(5):540-554
- Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications. Cell Tissue Res. 2012; 348(1):119-130
- Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther. 2012; 3(1):6
- Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant. 2011; 20(9):1409-1422
- Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy. 2010; 12(7):888-898
- Human platelet lysate permits scale-up of dental pulp stromal cells for clinical applications. Cytotherapy. 2011; 13(10):1221-1233
- Effect of platelet lysate on the functional and molecular characteristics of mesenchymal stem cells isolated form adipose tissue. Curr Stem Cell Res Ther. 2011; 6(2):105-114
- Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cell. 2009; 27(9):2331-2341
- Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007; 47(8):1436-1446
- Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005; 205(2):228-236